Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Ratings and Price Targets for Doximity NYSE DOCS

Elaine Mendonca by Elaine Mendonca
March 15, 2024
in Breaking News
0
Finance_ stocks to buy
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter

The latest data on Doximity (NYSE: DOCS) from the past quarter reveals a diverse range of opinions from analysts, ranging from bullish to bearish. Here is a breakdown of their recent ratings and any changes over the last 30 days compared to previous months:

– Total Ratings: Bullish (0), Somewhat Bullish (0), Indifferent (5), Somewhat Bearish (1), Bearish (0)
– Last 30 Days: Bullish (0), Somewhat Bullish (0), Indifferent (0), Somewhat Bearish (1), Bearish (0)
– 1 Month Ago: Bullish (0), Somewhat Bullish (0), Indifferent (1), Somewhat Bearish (0), Bearish (0)
– 2 Months Ago: Bullish (0), Somewhat Bullish (0), Indifferent (3), Somewhat Bearish (0), Bearish (0)
– 3 Months Ago: Bullish (0), Somewhat Bullish (0), Indifferent (1), Somewhat Bearish (0), Bearish (0)

Analysts have also provided 12-month price targets for Doximity, with an average target of $29.00, a high estimate of $32.00, and a low estimate of $25.00. This suggests a positive trend, with the current average target indicating a 16.0% increase from the previous average price target of $25.00.

Key actions from analysts include upgrades and changes in ratings, such as:

– Anne Samuel from JP Morgan upgraded the rating to Underweight with a price target of $25.00, up from $22.00.
– Michael Cherny at Leerink Partners initiated a Market Perform rating with a price target of $32.00.
– Jailendra Singh from Truist Securities upgraded the rating to Hold with a price target of $29.00, up from $28.00.
– Stan Berenshteyn at Wells Fargo upgraded the rating to Equal-Weight with a price target of $27.00, up from $25.00.
– Allen Lutz from B of A Securities upgraded the rating to Neutral with a price target of $32.00, up from $29.00.
– Allen Lutz from B of A Securities also upgraded the rating to Neutral with a price target of $29.00, up from $21.00.

These changes in ratings reflect analysts’ responses to market conditions and company performance, indicating adjustments in their recommendations based on recent developments.

DOCS Stock Shows Positive Momentum on March 15, 2024: Trading Above 200-Day Moving Average

On March 15, 2024, DOCS stock showed positive momentum as it traded in the middle of its 52-week range and above its 200-day simple moving average. The price of DOCS shares increased by $0.20 since the market last closed, representing a 0.72% rise. The stock opened at $27.76, which was $0.09 lower than its previous close. Overall, DOCS stock had a decent performance on March 15, 2024, with a slight increase in price and trading above its 200-day moving average. Investors will be keeping a close eye on the stock in the coming days to see if this positive momentum continues.

DOCS Stock Performance Analysis: Revenue Growth but Decline in Net Income

On March 15, 2024, investors were closely monitoring the stock performance of DOCS, a company that provides document management solutions. According to data from CNN Money, DOCS reported a total revenue of $419.05 million for the past year, which represented a 21.98% increase compared to the previous year. In the third quarter of the same year, the company generated $135.28 million in total revenue, marking a 19.08% increase from the previous quarter.

Despite the positive revenue growth, DOCS experienced a decline in net income over the past year. The company reported a net income of $112.82 million for the year, which represented a 15.34% decrease compared to the previous year. However, in the third quarter, DOCS saw a significant improvement in net income, with a reported figure of $47.96 million, marking a 56.71% increase from the previous quarter.

Earnings per share (EPS) also showed mixed results for DOCS. The company reported an EPS of $0.53 for the past year, which represented a 24.15% decrease compared to the previous year. However, in the third quarter, DOCS reported an EPS of $0.24, marking a substantial 63.39% increase from the previous quarter.

Overall, the stock performance of DOCS on March 15, 2024, reflected a mix of positive and negative indicators. Investors will continue to monitor the financial performance of DOCS closely to assess the company’s future prospects and potential for growth in the document management solutions industry.

Tags: DOCS
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
OHI stock news

Olin Announces Dividend Payout and Maintains Consistent Dividend History

Westinghouse Air Brake CEOs Insider Sell Causes Share Price Dip

Analyst Increases Price Target for Madrigal Pharmaceuticals Maintains Strong Buy Recommendation

Recommended

BigBearai Holdings Stock

BigBear.ai Faces Critical Test as Revenue Plummets and Losses Mount

6 months ago
D-Wave Quantum Stock

D-Wave Quantum: CFO’s Multi-Million Dollar Exit Amidst Major Capital Raise

4 months ago
Brightcove Stock

Bending Spoons Forges AI-Powered Streaming Future with Brightcove at the Core

6 months ago
Microsoft Stock

Microsoft Faces Critical Earnings Test Amid AI Expectations

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Regulatory Rebuke Sends ImmunityBio Shares Tumbling

Realty Income’s Strategic Financing Defies High Interest Rate Environment

IBM Shares Face Pressure from Analyst Downgrades and Acquisition Concerns

Battalion Oil Navigates Debt and Operational Overhaul

Divergent Analyst Views Highlight Coeur Mining’s Strategic Transition

Rocket Lab Stock Attracts Bullish Analyst Sentiment Amid Growth Trajectory

Trending

Bionxt Solutions Stock
Healthcare

BioNxt Solutions Enters Pivotal Commercial Phase with Key Patents

by SiterGedge
March 25, 2026
0

BioNxt Solutions has formally initiated the commercial phase for its sublingual drug delivery platform, marking a significant...

Take-Two Stock

GTA VI Launch Date Sets Stage for Take-Two’s Financial Horizon

March 25, 2026
Ocugen Stock

Ocugen Shares Slide Despite Positive Clinical Trial Results

March 25, 2026
ImmunityBio Stock

Regulatory Rebuke Sends ImmunityBio Shares Tumbling

March 25, 2026
Realty Income Stock

Realty Income’s Strategic Financing Defies High Interest Rate Environment

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • BioNxt Solutions Enters Pivotal Commercial Phase with Key Patents
  • GTA VI Launch Date Sets Stage for Take-Two’s Financial Horizon
  • Ocugen Shares Slide Despite Positive Clinical Trial Results

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com